MSLN and ovarian cancer: To model the binding of mesothelin to macrophages, we set up two types of in vitro assay systems using healthy donor monocytes and in vitro differentiated CD206low/high macrophages that were 1/ briefly incubated with conditioned media or with ascites fluids, or 2/ co-cultured for 3 days in transwells with OVCAR5 ovarian cancer cell line or with 293 MESOIg secreting GPI-truncated mesothelin [63] and, as controls, with wild type 293 cell line.